Loading stock data…
$4.42-0.10 (-2.21%)
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Abeona Therapeutics Inc. in the Healthcare sector is trading at $4.42 with a market capitalization of $288M. Wall Street consensus targets $18.88 (8 analysts), implying a +327.0% move over the next 12 months. The stock is currently near its 52-week low of $4.00, remaining 20.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.38M↑ | $8.72M↑ | $5.42M | $0↓ | $400,000 |
| Gross Profit | $7.20M↑ | $6.02M↑ | $2.58M↑ | -$488,000↓ | $300,000 |
| Operating Income | -$13.65M↑ | -$23.03M↓ | -$22.91M↑ | -$24.02M↓ | -$22.79M |
| Net Income | -$20.19M↓ | -$17.07M↑ | -$20.46M↓ | -$5.16M↓ | $108.83M |
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients wi...